Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This multi-centre, randomised, open-label phase II trial will compare the activity and toxicity of chemotherapy (weekly Paclitaxel) to a novel agent Olaparib, and also Olaparib to the combination of Olaparib and Cediranib in women with advanced ovarian cancer and a gene mutation (BRCA gene).

Olaparib is expected to be as active but less toxic than chemotherapy. This will be the first time that the combination of Olaparib and Cediranib has been tested in women with multiply relapsed platinum resistant ovarian cancer and a BRCA mutation.

OCTOVA is being funded by an educational grant from AstraZeneca (AZ) as part of the AZ-ECMC alliance. The trial is currently in setup and recruitment is expected to start in the summer of 2016. We plan to recruit 132 patients in 14 UK-wide sites.

Our team

  • Sarah Pearson

    OCTO Trial Management Director